N. Irwin

J. Holst, M. Rosenkilde, J. Windeløv, 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GluCreERT2;ROSA26-eYFP mice

F. Reimann, F. Gribble, N. Irwin, 2019, Peptides.

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice

N. Irwin, P. Flatt, R. Lafferty, 2022, The Journal of endocrinology.

Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice

N. Irwin, M. Ng, V. Gault, 2019, Clinical medicine insights. Endocrinology and diabetes.

DPP IV resistance and insulin releasing activity of a novel di‐substituted analogue of glucose‐dependent insulinotropic polypeptide, (Ser2–Asp13)GIP

N. Irwin, P. Flatt, V. Gault, 2003, Cell biology international.

Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists

N. Irwin, P. Flatt, R. Lafferty, 2022, Diabetes, obesity & metabolism.

Exendin‐4(Lys27PAL)/gastrin/xenin‐8‐Gln: A novel acylated GLP‐1/gastrin/xenin hybrid peptide that improves metabolic status in obese‐diabetic (ob/ob) mice

N. Irwin, P. Flatt, V. Gault, 2018, Diabetes/metabolism research and reviews.

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor.

D. Chappard, N. Irwin, P. Flatt, 2013, The Journal of endocrinology.

Evaluation of the role of N-methyl-D-aspartate (NMDA) receptors in insulin secreting beta-cells.

N. Irwin, P. Flatt, S. Patterson, 2016, European journal of pharmacology.

Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice

N. Irwin, P. Flatt, V. Gault, 2015, Diabetologia.

[Erratum] Effects of glucose-dependent insulinotropic polypeptide receptor knockout and a high-fat diet on cognitive function and hippocampal gene expression in mice.

N. Irwin, P. Flatt, V. Gault, 2015, Molecular medicine reports.

Evaluation of the long-term effects of gastric inhibitory polypeptide–ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice

N. Irwin, P. Flatt, I. Montgomery, 2012, British Journal of Nutrition.

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

C. Bailey, N. Irwin, P. Flatt, 2007, American journal of physiology. Endocrinology and metabolism.

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Andrew English, N. Irwin, P. Flatt, 2021, Frontiers in Endocrinology.

GABA and insulin but not nicotinamide augment α- to β-cell transdifferentiation in insulin-deficient diabetic mice.

N. Irwin, P. Flatt, A. Tarasov, 2022, Biochemical pharmacology.

Characterisation of the biological activity of xenin-25 degradation fragment peptides.

N. Irwin, P. Flatt, V. Gault, 2014, The Journal of endocrinology.

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

C. Bailey, N. Irwin, P. Flatt, 2009, Biochemical pharmacology.

The Enteroinsular Axis

N. Irwin, P. Flatt, V. Pathak, 2019, Nutrition and Diabetes.

Unraveling the Mechanisms Underlying Olanzapine-Induced Insulin Resistance

N. Irwin, V. Gault, 2013, Diabetes.

Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice

N. Irwin, P. Flatt, P. Flatt, 2013, Diabetologia.

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

N. Irwin, P. Flatt, V. Gault, 2015, Molecular and Cellular Endocrinology.

Expression of Gastrin Family Peptides in Pancreatic Islets and Their Role in &bgr;-Cell Function and Survival

N. Irwin, P. Flatt, D. Khan, 2018, Pancreas.

Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival.

Keith G. Thomas, N. Irwin, P. Flatt, 2019, Biochimie.

Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic mice.

N. Irwin, P. Flatt, A. Tarasov, 2022, The Journal of pharmacy and pharmacology.

Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.

N. Irwin, P. Flatt, V. Gault, 2011, The Journal of endocrinology.

Positive effects of GLP‐1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes

N. Irwin, P. Flatt, S. Patterson, 2015, Diabetes/metabolism research and reviews.

Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes

N. Irwin, S. McClean, V. Gault, 2021, Clinical medicine insights. Endocrinology and diabetes.

Passage and survival of infectious pancreatic necrosis (IPN) virus in the cow's gut after feeding a silage mixture containing IPN virus

N. Irwin, D. Smail, D. Harrison, 1993 .

Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice

N. Irwin, P. Flatt, N. Pathak, 2015, Molecular and Cellular Endocrinology.

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands

N. Irwin, P. Flatt, Neil Tanday, 2021, British journal of pharmacology.

Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential

N. Irwin, B. Green, P. Flatt, 2006, Peptides.

Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice.

N. Irwin, P. Flatt, P. Frizelle, 2013, The Journal of endocrinology.

A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus.

D. Chappard, N. Irwin, P. Flatt, 2016, Bone.

Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus

D. Chappard, N. Irwin, P. Flatt, 2015, Journal of cellular physiology.

Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength

D. Chappard, B. Thorens, N. Irwin, 2014, Osteoporosis International.

Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice

N. Irwin, P. Flatt, V. Gault, 2014, Neuropharmacology.

Metabolic effects of sustained activation of the GLP‐1 receptor alone and in combination with background GIP receptor antagonism in high fat–fed mice

N. Irwin, P. Flatt, P. McClean, 2009, Diabetes, obesity & metabolism.

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

C. Bailey, N. Irwin, P. Flatt, 2004, The Journal of endocrinology.

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.

N. Irwin, P. Flatt, V. Gault, 2008, Biochemical pharmacology.

Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.

C. Bailey, N. Irwin, P. Flatt, 2005, Diabetes.

Proglucagon-Derived Peptides as Therapeutics

N. Irwin, P. Flatt, R. Lafferty, 2021, Frontiers in Endocrinology.

Review: Maximising the therapeutic potential of glucagon-like peptide-1 in type 2 diabetes

N. Irwin, P. Flatt, Marc Moodley, 2009 .

Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update

N. Irwin, F. O'Harte, Ethan S Palmer, 2022, Clinical medicine insights. Endocrinology and diabetes.

Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice

N. Irwin, P. Flatt, K. Hunter, 2008, Peptides.

Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.

N. Irwin, P. Flatt, K. Hunter, 2008, European journal of pharmacology.

Pharmacology of Gut Hormone Mimetics for Obesity and Diabetes

N. Irwin, P. Flatt, R. Lafferty, 2021 .

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.

C. Hölscher, N. Irwin, P. Flatt, 2011, European journal of pharmacology.

Emerging therapeutic potential for peptide YY for obesity-diabetes

N. Irwin, P. Flatt, R. Lafferty, 2018, Peptides.

Pancreatic polypeptide revisited: Potential therapeutic effects in obesity-diabetes

N. Irwin, P. Flatt, Neil Tanday, 2022, Peptides.

Beneficial actions of a long‐acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation

N. Irwin, P. Flatt, R. Moffett, 2020, Diabetes, obesity & metabolism.

Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions

Andrew English, N. Irwin, 2019, Clinical medicine insights. Endocrinology and diabetes.

Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets

N. Irwin, P. Flatt, R. Cassidy, 2008, Biological chemistry.

A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes

C. Bailey, N. Irwin, P. Flatt, 2005, Journal of Pharmacology and Experimental Therapeutics.

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

C. Bailey, N. Irwin, P. Flatt, 2005, Journal of medicinal chemistry.

GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy

N. Irwin, P. Flatt, R. Lafferty, 2023, Expert opinion on pharmacotherapy.

Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice

N. Irwin, P. Flatt, B. Green, 2006, Experimental Gerontology.

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

C. Bailey, N. Irwin, P. Flatt, 2006, Journal of medicinal chemistry.

PYY (3-36) protects against high fat feeding induced changes of pancreatic islet and intestinal hormone content and morphometry.

N. Irwin, P. Flatt, D. Khan, 2023, Biochimica et biophysica acta. General subjects.

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

N. Irwin, P. Flatt, R. C. Moffett, 2012, Diabetologia.

Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice

N. Irwin, P. Flatt, B. Green, 2004, Biological chemistry.

(Pro3)GIP[mPEG]: novel, long‐acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity‐diabetes (diabesity) therapy

N. Irwin, P. Flatt, P. McClean, 2008, British journal of pharmacology.

Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

N. Irwin, P. Flatt, V. Pathak, 2018, Peptides.

Enteroendocrine hormone mimetics for the treatment of obesity and diabetes.

N. Irwin, P. Flatt, 2013, Current opinion in pharmacology.

(pGlu-Gln)-CCK-8[mPEG]: a novel, long-acting, mini-PEGylated cholecystokinin (CCK) agonist that improves metabolic status in dietary-induced diabetes.

N. Irwin, P. Flatt, P. Frizelle, 2013, Biochimica et biophysica acta.

Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.

N. Irwin, P. Flatt, R. Moffett, 2013, Biochemical pharmacology.

Active immunization against (Pro3)GIP improves metabolic status in high‐fat‐fed mice

N. Irwin, P. Flatt, I. Montgomery, 2010, Diabetes, obesity & metabolism.

High fat-fed diabetic mice present with profound alterations of the osteocyte network.

D. Chappard, R. Perrot, N. Irwin, 2016, Bone.

Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.

N. Irwin, C. Hewage, F. O'Harte, 2016, The Journal of endocrinology.

Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance

N. Irwin, P. Flatt, V. Gault, 2009, Peptides.

Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice

N. Irwin, P. Flatt, P. McClean, 2007, Experimental Gerontology.

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9–39)amide in obese diabetic (ob/ob) mice

N. Irwin, P. Flatt, B. Green, 2007, Biological chemistry.

GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice

D. Chappard, N. Irwin, P. Flatt, 2019, Peptides.

Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice

N. Irwin, P. Flatt, K. Hunter, 2007, Peptides.

Alteration of the bone tissue material properties in type 1 diabetes mellitus: A Fourier transform infrared microspectroscopy study.

D. Chappard, N. Irwin, P. Flatt, 2015, Bone.

Metabolic and structural properties of human obestatin {1–23} and two fragment peptides

N. Irwin, P. Flatt, B. Green, 2010, Peptides.

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

N. Irwin, P. Flatt, S. Patterson, 2009, Biological chemistry.

Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.

N. Irwin, P. Flatt, B. Green, 2006, European journal of pharmacology.

Short-term CFTR inhibition reduces islet area in C57BL/6 mice

N. Irwin, M. Flodström-Tullberg, C. Kelly, 2019, Scientific Reports.

Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice

C. Bailey, N. Irwin, P. Flatt, 2006, Journal of Pharmacology and Experimental Therapeutics.

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues

C. Bailey, N. Irwin, P. Flatt, 2004, Biological chemistry.

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

C. Bailey, N. Irwin, P. Flatt, 2003, Journal of molecular endocrinology.

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

N. Irwin, P. Flatt, B. Green, 2007, European journal of pharmacology.

Comparison of the subchronic antidiabetic effects of DPP IV–resistant GIP and GLP‐1 analogues in obese diabetic (ob/ob) mice

N. Irwin, P. Flatt, P. McClean, 2007, Journal of peptide science : an official publication of the European Peptide Society.

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37)

C. Bailey, N. Irwin, P. Flatt, 2005, Biological chemistry.

Chronic treatment with exendin(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice.

C. Bailey, N. Irwin, P. Flatt, 2005, The Journal of endocrinology.

Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice

F. Reimann, F. Gribble, N. Irwin, 2021, Frontiers in Endocrinology.

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

C. Bailey, N. Irwin, P. Flatt, 2004, Metabolism: clinical and experimental.

Long-term administration of PACAP receptor antagonist, PACAP(6-27), impairs glucose tolerance and insulin sensitivity in obese diabetic ob/ob mice

N. Irwin, P. Flatt, B. Green, 2006, Peptides.

The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia

N. Irwin, P. Flatt, R. Lafferty, 2023, Molecular and Cellular Endocrinology.

Ψ-xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.

G. Hamscher, N. Irwin, V. Gault, 2020, The Journal of endocrinology.

A novel peptide isolated from Aphonopelma chalcodes tarantula venom with benefits on pancreatic islet function and appetite control.

N. Irwin, S. McClean, V. Gault, 2023, Biochemical pharmacology.

Antidiabetic action of nateglinide includes augmentation of glucagon-like peptide-1 activity mediated partly through inhibition of DPP IV mediated degradation

N. Irwin, P. Flatt, B. Green, 2007 .

C‐terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta‐cell function

N. Irwin, R. Lafferty, P. Flatt, 2018, Biochemical pharmacology.

Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function.

N. Irwin, S. McClean, V. Gault, 2023, European Journal of Pharmacology.

RYGB surgery has modest effects on intestinal morphology and gut hormone populations in the bypassed biliopancreatic limb but causes reciprocal changes in GLP-2 and PYY in the alimentary limb

N. Irwin, P. Flatt, D. Khan, 2023, PloS one.

Sustained treatment with a stable long‐acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes

N. Irwin, P. Flatt, V. Gault, 2015, Diabetes, obesity & metabolism.

Islet distribution of Peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival

N. Irwin, P. Flatt, D. Khan, 2016, Molecular and Cellular Endocrinology.

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

N. Irwin, P. Flatt, S. McClean, 2018, Biochemical pharmacology.

Enzymatically stable analogue of the gut‐derived peptide xenin on beta‐cell transdifferentiation in high fat fed and insulin‐deficient Ins1Cre/+;Rosa26‐eYFP mice

N. Irwin, V. Gault, R. Moffett, 2020, Diabetes/metabolism research and reviews.

Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance.

N. Irwin, P. Flatt, R. Charlotte Moffett, 2020, Biochemical pharmacology.

Evaluation of the role of N-methyl-D-aspartate (NMDA) receptors in insulin secreting beta-cells.

N. Irwin, S. Patterson, R. Moffett, 2016, European journal of pharmacology.

M. Tambuwala, P. McCarron, N. Irwin, 2018, Pharmaceutical development and technology.

Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress

B. Thorens, N. Irwin, P. Flatt, 2014, PloS one.

Metabolic responses and benefits of GLP-1 receptor ligands

N. Irwin, P. Flatt, N. Tanday, 2021 .

desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

N. Irwin, Z. Franklin, F. O’Harte, 2013, European journal of pharmacology.

Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice

N. Irwin, P. Flatt, J. McCluskey, 2013, Gene Therapy.

Sex-based impact of pancreatic islet stressors in GluCreERT2/Rosa26-eYFP mice

N. Irwin, P. Flatt, Vaibhav Dubey, 2023, The Journal of endocrinology.

Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties.

D. Chappard, M. Audran, N. Irwin, 2014, Bone.

GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice

N. Irwin, P. Flatt, D. Khan, 2023, Peptides.

Have we got the guts to maintain target weight?

N. Irwin, 2023, Acta physiologica.

Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells

C. Bailey, N. Irwin, P. Flatt, 2010, Biological chemistry.

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes

N. Irwin, V. Gault, S. Craig, 2018, Diabetes/metabolism research and reviews.

NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?

N. Irwin, R. Lafferty, Peter R. Flatt, 2024, Peptides.

Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16)

N. Irwin, P. Flatt, B. Green, 2006, Regulatory Peptides.

Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice.

N. Irwin, Z. Franklin, F. O’Harte, 2014, Biological chemistry.

Effects of chronic exposure of clonal β‐cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP‐1

N. Irwin, P. Flatt, V. Pathak, 2014, Diabetes, obesity & metabolism.